Human relevance of NRAS/BRAF mouse melanoma models.

[1]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Stephen C. J. Parker,et al.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.

[3]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[4]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[5]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[6]  Janet Kelso,et al.  High‐throughput sequencing of the melanoma genome , 2013, Experimental dermatology.

[7]  K. Brown,et al.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma , 2012, Pigment cell & melanoma research.

[8]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.

[9]  Hubing Shi,et al.  MDM4 is a key therapeutic target in cutaneous melanoma , 2012, Nature Medicine.

[10]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[11]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[12]  H. Horlings,et al.  Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.

[13]  F. Rambow,et al.  General strategy to analyse coat colour phenotypes in mice , 2012, Pigment cell & melanoma research.

[14]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[15]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[16]  F. Rambow,et al.  General strategy to analyse melanoma in mice , 2011, Pigment cell & melanoma research.

[17]  R. Ballotti,et al.  Biological and mathematical modeling of melanocyte development , 2011, Development.

[18]  M. Bosenberg,et al.  Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis , 2010, Pigment cell & melanoma research.

[19]  Minjung Kim.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis , 2010, Small GTPases.

[20]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[21]  J. Krishnamurthy,et al.  Somatic p16INK4a loss accelerates melanomagenesis , 2010, Oncogene.

[22]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Reis-Filho,et al.  Oncogenic Braf induces melanocyte senescence and melanoma in mice. , 2009, Cancer cell.

[24]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[25]  L. Larue,et al.  Cutaneous melanoma in genetically modified animals. , 2007, Pigment cell research.

[26]  F. Luciani,et al.  Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. , 2007, Genes & development.

[27]  L. Chin,et al.  Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice , 2006, Genesis.

[28]  L. Larue,et al.  Spatiotemporal gene control by the Cre‐ERT2 system in melanocytes , 2006, Genesis.

[29]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[30]  A. Trumpp,et al.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. , 2005, Cancer research.

[31]  Daniel Pinkel,et al.  Classifying melanocytic tumors based on DNA copy number changes. , 2003, The American journal of pathology.

[32]  L. Larue,et al.  SP-14 Cre-mediated recombination in the skin melanocyte lineage , 2003 .

[33]  F. Haluska,et al.  PTEN signaling pathways in melanoma , 2003, Oncogene.

[34]  L. Chin,et al.  Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[36]  N. Hayward,et al.  Nuclear PTEN expression and clinicopathologic features in a population‐based series of primary cutaneous melanoma , 2002, International journal of cancer.

[37]  L. Chin,et al.  Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[39]  J. J. van den Oord,et al.  Expression of the endothelin-B receptor in pigment cell lesions of the skin , 2001, Virchows Archiv.

[40]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[41]  L. Chin.  Modeling malignant melanoma in mice: pathogenesis and maintenance , 1999, Oncogene.

[42]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[43]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[44]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[45]  B. Seizinger,et al.  Chromosome 17 allelic loss and NF1-GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis. , 1996, The Journal of investigative dermatology.

[46]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC 1 mutations in melanoma , 2016 .

[47]  J. Krishnamurthy,et al.  Somatic p 16 INK 4 a Loss Accelerates Melanomagenesis , 2010 .

[48]  A. Glick,et al.  Endothelin 3 induces skin pigmentation in a keratin-driven inducible mouse model. , 2008, The Journal of investigative dermatology.

[49]  D. Pinkel,et al.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.

[50]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.